Get the Stockscreener App
44.06
0.92%
0.40
Xenon Pharmaceuticals Inc stock is traded at $44.06, with a volume of 807.45K.
It is up +0.92% in the last 24 hours and up +11.04% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$43.66
Open:
$43.8
24h Volume:
807.45K
Relative Volume:
1.03
Market Cap:
$3.40B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-16.08
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
-2.11%
1M Performance:
+11.04%
6M Performance:
+34.33%
1Y Performance:
+11.69%
1-Day Range:
$43.28
$44.57
1-Week Range:
$42.89
$46.60
52-Week Range:
$26.74
$46.60
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
44.06 | 3.37B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 7th Largest Position - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $48.00 Price Target at Wells Fargo & Company - Defense World
Wells Fargo Maintains Xenon Pharmaceuticals (XENE) Overweight Recommendation - Nasdaq
XENE Stock Update: Wells Fargo Raises Price Target to $48 | XENE - GuruFocus
Russell Investments Group Ltd. Decreases Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline - MSN
Ian Mortimer Sells 10,830 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock - MarketBeat
Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells 14,375 Shares of Stock - MarketBeat
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares By Investing.com - Investing.com South Africa
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares - Investing.com
Xenon Pharmaceuticals unveils promising long-term epilepsy treatment data - MSN
Marshall Wace LLP Acquires 262,109 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year High – Here’s What Happened - Defense World
Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data? - Yahoo Finance
Xenon Pharmaceuticals issues equity inducement grants to new employees - MSN
New York State Common Retirement Fund Purchases 24,100 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Rhumbline Advisers Grows Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 52-Week HighHere's What Happened - MarketBeat
Xenon Pharmaceuticals Inc. $XENE is Affinity Asset Advisors LLC's 3rd Largest Position - MarketBeat
Xenon Pharmaceuticals Inc. $XENE is Affinity Asset Advisors LLC’s 3rd Largest Position - Defense World
Evaluating Xenon Pharmaceuticals (XENE)’s Valuation After Its Recent Share Price Rebound - Sahm
Xenon Pharmaceuticals stock hits 52-week high at 45.09 USD By Investing.com - Investing.com India
XENE Unveils Promising Data on Epilepsy Treatment Advances - GuruFocus
Xenon Pharmaceuticals stock hits 52-week high at 45.09 USD - Investing.com
Xenon Pharmaceuticals Unveils Promising Long-Term Epilepsy Treatment Data - TipRanks
Xenon Pharmaceuticals Reports Significant Long-Term Efficacy of Azetukalner in Epilepsy at AES 2025 - Quiver Quantitative
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 - The Manila Times
Saturn V Capital Management LP Boosts Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How Xenon Pharmaceuticals Inc. stock performs in rate cut cyclesJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - Newser
Ian Mortimer, Xenon Pharma CEO, sells $4365 in shares By Investing.com - Investing.com Canada
Ian Mortimer, Xenon Pharma CEO, sells $4365 in shares - Investing.com
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report? - sharewise.com
Xenon Pharmaceuticals to Host Webinar on Epilepsy Data and Commercialization Plans - TipRanks
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 - GlobeNewswire
JPMorgan Chase & Co. Cuts Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Loomis Sayles & Co. L P Sells 15,846 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
American Century Companies Inc. Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Expands 2025 Equity Incentive Plan - TipRanks
(XENE) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Ameritas Investment Partners Inc. Acquires Shares of 7,758 Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Franklin Resources Inc. Purchases 175,346 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Geode Capital Management LLC Purchases 900,746 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals (XENE): Evaluating Valuation as New Epilepsy and Dravet Data Draw Investor Attention - Sahm
Xenon Reports Second Quarter 2025 Financial Results & Business Update - ADVFN
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):